Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Evolved By Nature Inc. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 7 distinct art units, indicating a broad examination footprint for the active matters. Such a wide spread suggests that the company's innovations touch upon diverse sub-specialties within the biotechnology sector, requiring legal teams to navigate the specific standards of various USPTO divisions simultaneously.
The prosecution workload is handled by distinct examiners, creating a distributed relationship between pending actions and assigned officials. PAK, MICHAEL D is identified as the busiest examiner, though this individual currently oversees only 1 pending action. This lack of concentration among examiners means that no specific official's feedback dominates the portfolio's current trajectory, and practitioners should prepare for varied examination styles across all cases.
The high degree of fragmentation across the art units and examiners implies that the company faces a broad array of individual examiner preferences and interpretations. Without a central official to focus on, the prosecution strategy must remain flexible to accommodate the unique procedural nuances found in each area of the biotechnology field. This structure highlights the technical breadth of the company's current patent filings within the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 6 (86%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002337 | Silk-Hyaluronic Acid Compositions For Tissue Filling, Tissue Spacing, and Tissue Bulking | LEE, HOI YAN NMN | 201d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002337 | Silk-Hyaluronic Acid Compositions For Tissue Filling, Tissue Spacing, and Tissue Bulking | LEE, HOI YAN NMN | 201d overdue |
| 16626081 | SILK-HYALURONIC ACID BASED TISSUE FILERS AND METHODS OF USING THE SAME | PARK, HAEJIN S | 81d overdue |
| 19079960 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | PAK, MICHAEL D | — |
| 18982351 | SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME | TRUONG, QUANGLONG N | — |
| 18503064 | Silk Protein Fragment Compositions and Articles Manufactured Therefrom | EIX, EMILY FAY | — |
| 17861936 | Silk Protein Fragment Compositions and Articles Manufactured Therefrom | FISCHER, JOSEPH | — |
| 17616897 | SILK STIMULATED COLLAGEN PRODUCTION AND METHODS OF USE THEREOF | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1615 | 1 |
| 1653 | 1 |
| 1693 | 1 |
| 1658 | 1 |
| 1691 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19079960 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | PAK, MICHAEL D | 1674 | §112DP | Final Rejection | — | Pending | Mar 14, 2025 |
| 18982351 | SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME | TRUONG, QUANGLONG N | 1615 | §103DP | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18503064 | Silk Protein Fragment Compositions and Articles Manufactured Therefrom | EIX, EMILY FAY | 1653 | §103§112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18002337 | Silk-Hyaluronic Acid Compositions For Tissue Filling, Tissue Spacing, and Tissue Bulking | LEE, HOI YAN NMN | 1693 | §102§103§112Other | Non-Final OA | 201d overdue | Pending | Dec 19, 2022 |
| 17861936 | Silk Protein Fragment Compositions and Articles Manufactured Therefrom | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Jul 11, 2022 |
| 17616897 | SILK STIMULATED COLLAGEN PRODUCTION AND METHODS OF USE THEREOF | CREWS, JARET JAMES | 1691 | §103DP | Non-Final OA | — | Pending | Dec 06, 2021 |
| 16626081 | SILK-HYALURONIC ACID BASED TISSUE FILERS AND METHODS OF USING THE SAME | PARK, HAEJIN S | 1614 | §103DP | Non-Final OA | 81d overdue | Pending | Dec 23, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEvolved By Nature Inc. has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Michael D Pak has the most, with 1 of Evolved By Nature Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
